Lead

Chinese biotechnology company WuXi AppTec has initiated legal action against the US government over its placement on a Pentagon list of companies allegedly linked to China’s military. The lawsuit was filed in a Washington federal court.

Coverage comparison

According to the South China Morning Post, the company's complaint calls its inclusion on the list “arbitrary,” “capricious,” and “the product of political pressure.” The filing also accuses the US government of inflicting substantial reputational and operational harm on the company by branding it a national security threat without legal or factual basis.

A Pentagon spokesman said the agency does not discuss pending litigation. The lawsuit seeks WuXi AppTec’s removal from the list.

Reporting indicates the legal action came just days after the Pentagon expanded its blacklist to include 188 companies, up from 134. The expansion is seen as reflecting US concerns that China's military could leverage the country's private sector for advancements amid elevated geopolitical tensions between the two nations.

Key claims

  • WuXi AppTec alleges the US government caused it substantial reputational and operational harm by adding it to the military-linked companies list.
  • The Pentagon expanded its list of Chinese military companies to 188 entities, with WuXi AppTec being one of the newly added names in the healthcare sector.
  • A single source reports that US President Donald Trump met China's leader Xi Jinping in Beijing less than a month before the lawsuit was filed, with the two leaders maintaining a truce on trade issues.

Perspectives

Despite the political friction, analysts suggest the blacklisting may not significantly hamper multinational drug makers from collaborating with China's biopharmaceutical firms. Cui Cui, head of healthcare research for Asia at Jefferies, is quoted as seeing minimal impact, explaining that multinational pharmaceutical companies still prefer “made-in-China” for cost efficiency.

Cui noted the global pharmaceutical industry is seeking “cost flexibility amid mounting pressure from drug pricing reforms and looming blockbuster patent expirations,” which gives China a competitive edge.

The legal action is not the first time US authorities have targeted Chinese biotech firms. The BioSecure Act, first introduced in Congress in late 2023, initially named five Chinese life-sciences companies, including WuXi AppTec and BGI Group, as entities US federal agencies would be barred from contracting with. However, by the time the bill was signed into law in December, all five company names had been removed.

The market reaction to the blacklisting was notable but contained. WuXi AppTec’s Hong Kong-traded shares tumbled as much as 5.2 per cent following the announcement before recovering to close down 3.7 per cent. The following day, the shares rose 2.3 per cent.

Industry players contend that the political headwinds are unlikely to derail healthcare collaboration, as the shared drive to improve patient outcomes and reduce costs will ultimately prevail.